Mortality rate was significantly higher in 122 cancer patients with COVID-19 than 1220 patients without cancer (OR 1.653, p=0.014), especially in patients with lung cancer (OR 4.664, p=0.002). 55 patients diagnosed with cancer within one year had a significantly higher mortality (OR 2.32, p=0.004). Stage 4, but not earlier stages of, cancer at diagnosis had much higher mortality (OR 2.82, p<0.001). Progression of cancer was highly predictive of mortality (OR 4.60, p=0.00002). SACT had no

more »

... cant effect on mortality from COVID-19 disease when compared with cancer patients who had no active treatment. However, cancer patients that did not have SACT within 3 months were more likely to die (OR 1.80, p=0.025). Conclusion Among patients with cancer and COVID-19, mortality was high and associated with cancer-specific features. There was no evidence cancer patients on systemic anti-cancer treatments possessed higher mortality from COVID-19 disease, which correlates with findings from COVID-19 and cancer registries 1 . Patients that did not receive SACT within 3 months before COVID-19 and therefore more likely to have palliative treatment did demonstrate high mortality. Larger studies are needed to confirm the risk of mortality and timing of SACT before COVID-19 disease.